Generation of HIV latency during thymopoiesis
- PMID: 11283673
- DOI: 10.1038/86531
Generation of HIV latency during thymopoiesis
Abstract
The use of combination antiretroviral therapy results in a substantial reduction in viremia, a rebound of CD4+ T cells and increased survival for HIV-infected individuals. However, this treatment does not result in the total eradication of HIV. Rather, the virus is thought to remain latent in a subset of cells, where it avoids elimination by the immune system. In this state the virus is capable of reactivation of productive infection following cessation of therapy. These latently infected cells are very few in number and it has thus been difficult to determine their origin and to study the molecular nature of the latent viral genome. HIV replication is linked to cellular gene transcription and requires target cell activation. Therefore, should an activated, infected cell become transcriptionally inactive prior to cytopathic effects, the viral genome might be maintained in a latent state. We used the SCID-hu (Thy/Liv) mouse model to establish that activation-inducible HIV can be generated at high frequency during thymopoiesis, a process where previously activated cells mature towards quiescence. Moreover, we showed that these cells can be exported into the periphery where the virus remains latent until T-cell receptor stimulation, indicating that the thymus might be a source of latent HIV in humans.
Comment in
-
A new latent HIV reservoir.Nat Med. 2001 Apr;7(4):404-5. doi: 10.1038/86455. Nat Med. 2001. PMID: 11283657 No abstract available.
Similar articles
-
The human HIV/peripheral blood lymphocyte (PBL)-SCID mouse. A modified human PBL-SCID model for the study of HIV pathogenesis and therapy.J Immunol. 1995 Jun 15;154(12):6612-23. J Immunol. 1995. PMID: 7759895
-
Divergent effects of chronic HIV-1 infection on human thymocyte maturation in SCID-hu mice.J Immunol. 1995 Jan 15;154(2):907-21. J Immunol. 1995. PMID: 7814892
-
Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals.Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1908-13. doi: 10.1073/pnas.0437640100. Epub 2003 Jan 27. Proc Natl Acad Sci U S A. 2003. PMID: 12552096 Free PMC article.
-
Molecular biological assessment methods and understanding the course of the HIV infection.APMIS Suppl. 2003;(114):1-37. APMIS Suppl. 2003. PMID: 14626050 Review.
-
Latency: the hidden HIV-1 challenge.Retrovirology. 2006 Jan 16;3:7. doi: 10.1186/1742-4690-3-7. Retrovirology. 2006. PMID: 16412247 Free PMC article. Review.
Cited by
-
Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency.Mol Ther. 2016 Sep;24(9):1528-37. doi: 10.1038/mt.2016.117. Epub 2016 Jun 6. Mol Ther. 2016. PMID: 27434587 Free PMC article.
-
Animal models to achieve an HIV cure.Curr Opin HIV AIDS. 2016 Jul;11(4):432-41. doi: 10.1097/COH.0000000000000290. Curr Opin HIV AIDS. 2016. PMID: 27152962 Free PMC article. Review.
-
Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.J Virol. 2006 Oct;80(20):10229-36. doi: 10.1128/JVI.00965-06. J Virol. 2006. PMID: 17005700 Free PMC article.
-
Phylodynamics of HIV-1 in lymphoid and non-lymphoid tissues reveals a central role for the thymus in emergence of CXCR4-using quasispecies.PLoS One. 2007 Sep 26;2(9):e950. doi: 10.1371/journal.pone.0000950. PLoS One. 2007. PMID: 17895991 Free PMC article.
-
Syndecans serve as attachment receptors for human immunodeficiency virus type 1 on macrophages.J Virol. 2001 Oct;75(19):9187-200. doi: 10.1128/JVI.75.19.9187-9200.2001. J Virol. 2001. PMID: 11533182 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials